Compare WVVI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVVI | RANI |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 134.6M |
| IPO Year | N/A | 2021 |
| Metric | WVVI | RANI |
|---|---|---|
| Price | $2.84 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 7.3K | ★ 2.6M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,366,837.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.49 | $0.39 |
| 52 Week High | $7.18 | $3.87 |
| Indicator | WVVI | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 40.73 |
| Support Level | $2.71 | $1.52 |
| Resistance Level | $3.00 | $1.67 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 87.23 | 3.04 |
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.